In vivo experimental mouse model to test CD19CAR T cells generated with different methods

Area of Science:

• Immunotherapy
• Oncology
• Pre-clinical Research

Background:

• Pre-clinical evaluation of CAR T-cells is crucial for assessing therapeutic potential.
• In vivo studies using murine models are standard for testing CAR T-cell efficacy and safety.
• Evaluating CAR T-cell capacity to control cancer progression provides key efficacy data.

Purpose of the Study:

• To provide a detailed protocol for in vivo testing of CAR T-cells.
• To establish a method for assessing the efficacy of CD19CAR T-cells.
• To utilize an aggressive lymphoma model for robust pre-clinical evaluation.

Main Methods:

• Development of a protocol for in vivo CAR T-cell efficacy testing.
• Utilizing immunodeficient murine models for pre-clinical studies.
• Employing human cancer cell lines and genetically modified human T-cells in vivo.
• Using a validated anti-B-cell marker, CD19CAR, for targeted therapy.

Main Results:

• The protocol allows for the assessment of CAR T-cell control over cancer progression in vivo.
• Demonstrates the application of CD19CAR T-cells in an aggressive lymphoma model.
• Provides a framework for evaluating the efficacy of CAR T-cell therapies.

Conclusions:

• The presented protocol offers a standardized approach for in vivo CAR T-cell efficacy testing.
• This method is valuable for advancing the pre-clinical evaluation of immunotherapies.
• The study validates the use of CD19CAR T-cells in a relevant aggressive lymphoma model.